Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.

Adult Antibodies, Bispecific / therapeutic use B-Lymphocytes Hematopoietic Stem Cell Transplantation Humans Neoplasm, Residual Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Acute lymphoblastic leukemia allogeneic hematopoietic stem cell transplantation blinatumomab immuno-oncotherapy minimal residual disease

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
11 2020
Historique:
pubmed: 4 7 2020
medline: 28 4 2021
entrez: 4 7 2020
Statut: ppublish

Résumé

Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In BLAST study (NCT01207388), adults with BCP-ALL in remission with MRD after chemotherapy received blinatumomab, a CD19 BiTE

Identifiants

DOI: 10.1080/10428194.2020.1780583 PMID: 32619115
pubmed: 32619115
doi: 10.1080/10428194.2020.1780583
doi:

Substances chimiques

Antibodies, Bispecific 0
blinatumomab 4FR53SIF3A

Banques de données

ClinicalTrials.gov
['NCT01207388']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2665-2673

Commentaires et corrections

Type : CommentIn

Auteurs

Nicola Gökbuget (N)

University Hospital, Frankfurt, Germany.

Gerhard Zugmaier (G)

Amgen Research (Munich), GmbH, Munich, Germany.

Hervé Dombret (H)

University Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France.

Anthony Stein (A)

City of Hope National Medical Center, Duarte, CA, USA.

Massimiliano Bonifacio (M)

Department of Medicine, Section of Hematology, Verona University, Verona, Italy.

Carlos Graux (C)

CHU UCL Namur - Site Godinne, Université Catholique de Louvain, Yvoir, Belgium.

Christoph Faul (C)

University Hospital and Comprehensive Cancer Center Tübingen, Universitätsklinikum Tübingen, Tübingen, Germany.

Monika Brüggemann (M)

Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

Kate Taylor (K)

Amgen Limited, Cambridge, UK.

Noemi Mergen (N)

Amgen Research (Munich), GmbH, Munich, Germany.

Albrecht Reichle (A)

Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.

Heinz-August Horst (HA)

Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

Violaine Havelange (V)

Department of Hematology, Cliniques Universitaires St. Luc, Brussels, Belgium.

Max S Topp (MS)

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany and.

Ralf C Bargou (RC)

Comprehensive Cancer Center Mainfranken, Uniklinikum Würzburg, Würzburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Curative outcomes following blinatumomab in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps bispécifiques › Curative outcomes following blinatumomab in...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes B › Curative outcomes following blinatumomab in...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Curative outcomes following blinatumomab in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Curative outcomes following blinatumomab in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Maladie résiduelle › Curative outcomes following blinatumomab in...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie-lymphome lymphoblastique à précurseurs B et T › Leucémie-lymphome lymphoblastique à précurseurs B › Curative outcomes following blinatumomab in...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie-lymphome lymphoblastique à précurseurs B et T › Curative outcomes following blinatumomab in...